HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP

被引：0
|
作者：
Muggiano, A. [1 ]
Mulas, C. [1 ]
Fiori, B. [1 ]
Liciardi, G. [1 ]
Pintus, M. [1 ]
Tanca, L. [1 ]
Tedde, A. [1 ]
Turno, R. [1 ]
Desogus, A. [1 ]
机构：
[1] Osped Oncolog A Businco, Div Med Oncol 1, Cagliari, Italy
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 86
页数：2
相关论文
共 50 条
  • [31] Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels
    Vihinen, Pia
    Tervahartiala, Taina
    Sorsa, Timo
    Hansson, Johan
    Bastholt, Lars
    Aamdal, Steinar
    Stierner, Ulrika
    Pyrhonen, Seppo
    Syrjanen, Kari
    Lundin, Johan
    Hernberg, Micaela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (02) : 173 - 180
  • [32] The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma
    Van Anh Trinh
    Zobniw, Chrystia
    Hwu, Wen-Jen
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (08) : 933 - 940
  • [33] A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
    Messori, A
    Becagli, P
    Trippoli, S
    Tendi, E
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (09) : 1373 - 1379
  • [34] Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684 (Reprinted from vol 14, pg 7-17, 1996)
    Kirkwood, John M.
    Strawderman, Myla Hunt
    Ernstoff, Marc S.
    Smith, Thomas J.
    Borden, Ernest C.
    Blum, Ronald H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 425 - 435
  • [35] Adjuvant therapy of high-risk melanoma: The role of high-dose interferon alpha-2b
    Kirkwood, JM
    Strawderman, MH
    Ernstoff, MS
    Smith, T
    Borden, E
    Blum, R
    ADJUVANT THERAPY OF CANCER VIII, 1997, 8 : 251 - 257
  • [36] Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines
    Vetto, John T.
    CANCERS, 2024, 16 (14)
  • [37] Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609
    Tarhini, Ahmad A.
    Lee, Sandra J.
    Hodi, F. Stephen
    Rao, Uma N. M.
    Cohen, Gary I.
    Hamid, Omid
    Hutchins, Laura F.
    Sosman, Jeffrey A.
    Kluger, Harriett M.
    Eroglu, Zeynep
    Koon, Henry B.
    Lawrence, Donald P.
    Kendra, Kari L.
    Minor, David R.
    Lee, Carrie B.
    Albertini, Mark R.
    Flaherty, Lawrence E.
    Petrella, Teresa M.
    Streicher, Howard
    Sondak, Vernon K.
    Kirkwood, John M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 567 - +
  • [38] Use of adjuvant interferon alfa-2b or ipilimumab 10 mg/kg for high-risk patients with melanoma, and associated adverse events and duration of therapy
    Tarhini, Ahmad
    Gupte-Singh, Komal
    You, Min
    Gupta, Amit
    Kim, Le Trong
    Rao, Sumati
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma
    Salans, Mia
    Courtney, Patrick Travis
    Yip, Anthony
    Murphy, James D.
    CANCER MEDICINE, 2021, 10 (19): : 6618 - 6626
  • [40] Long-term follow-up after high-dose therapy for high-risk multiple myeloma
    Barlogie, B
    Jagannath, S
    Naucke, S
    Mattox, S
    Bracy, D
    Crowley, J
    Tricot, G
    Alexanian, R
    BONE MARROW TRANSPLANTATION, 1998, 21 (11) : 1101 - 1107
12345